BRIEF-Lilly's Orforglipron Outperforms Oral Semaglutide Across Primary & Key Secondary Endpoints

Like
Comment
Favorite

BRIEF-Lilly's Orforglipron Outperforms Oral Semaglutide Across Primary & Key Secondary Endpoints

Reuters02-26 19:30

BRIEF-Lilly's Orforglipron Outperforms Oral Semaglutide Across Primary & Key Secondary Endpoints

Feb 26 (Reuters) - Eli Lilly and Co LLY.N:

LILLY'S ORAL GLP-1, ORFORGLIPRON, DELIVERED SUPERIOR BLOOD SUGAR CONTROL & WEIGHT LOSS VERSUS ORAL SEMAGLUTIDE IN TYPE 2 DIABETES TRIAL
ELI LILLY: IN ACHIEVE-3, ORFORGLIPRON OUTPERFORMED ORAL SEMAGLUTIDE ACROSS PRIMARY & ALL KEY SECONDARY ENDPOINTS
ELI LILLY: TREATMENT DISCONTINUATION RATES DUE TO ADVERSE EVENTS WERE 9.7% (36 MG) FOR ORFORGLIPRON VERSUS. 4.9% (14 MG) FOR ORAL SEMAGLUTIDE
ELI LILLY: SUBMITTED ORFORGLIPRON TO REGULATORS IN OVER 40 COUNTRIES, WITH POTENTIAL US ACTION FOR OBESITY IN Q2 2026
ELI LILLY: IN KEY SECONDARY ENDPOINT, PARTICIPANTS ON ORFORGLIPRON 36 MG LOST 19.7 LBS (9.2%) VERSUS 11.0 LBS (5.3%) WITH ORAL SEMAGLUTIDE 14 MG
ELI LILLY: ORFORGLIPRON SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE ACROSS KEY CARDIOVASCULAR RISK FACTORS
ELI LILLY: FOR PRIMARY ENDPOINT, ORFORGLIPRON 36 MG LOWERED A1C BY 2.2% VERSUS. 1.4% WITH ORAL SEMAGLUTIDE 14 MG IN ACHIEVE-3

Further company coverage: LLY.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2614416950?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614416950","market":"nz","top_or_hot":-1,"title":"BRIEF-Lilly's Orforglipron Outperforms Oral Semaglutide Across Primary & Key Secondary Endpoints","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Lilly's Orforglipron Outperforms Oral Semaglutide Across Primary &amp; Key Secondary Endpoints</title></head><body><p><span>Feb 26 (Reuters)</span><span> - </span>Eli Lilly and Co <span>LLY.N</span>:</p><ul><li><p>LILLY'S ORAL GLP-1, ORFORGLIPRON, DELIVERED SUPERIOR BLOOD SUGAR CONTROL &amp; WEIGHT LOSS VERSUS ORAL SEMAGLUTIDE IN TYPE 2 DIABETES TRIAL</p></li><li><p>ELI LILLY: IN ACHIEVE-3, ORFORGLIPRON OUTPERFORMED ORAL SEMAGLUTIDE ACROSS PRIMARY &amp; ALL KEY SECONDARY ENDPOINTS</p></li><li><p>ELI LILLY: TREATMENT DISCONTINUATION RATES DUE TO ADVERSE EVENTS WERE 9.7% (36 MG) FOR ORFORGLIPRON VERSUS. 4.9% (14 MG) FOR ORAL SEMAGLUTIDE</p></li><li><p>ELI LILLY: SUBMITTED ORFORGLIPRON TO REGULATORS IN OVER 40 COUNTRIES, WITH POTENTIAL US ACTION FOR OBESITY IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>ELI LILLY: IN KEY SECONDARY ENDPOINT, PARTICIPANTS ON ORFORGLIPRON 36 MG LOST 19.7 LBS (9.2%) VERSUS 11.0 LBS (5.3%) WITH ORAL SEMAGLUTIDE 14 MG</p></li><li><p>ELI LILLY: ORFORGLIPRON SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE ACROSS KEY CARDIOVASCULAR RISK FACTORS</p></li><li><p>ELI LILLY: FOR PRIMARY ENDPOINT, ORFORGLIPRON 36 MG LOWERED A1C BY 2.2% VERSUS. 1.4% WITH ORAL SEMAGLUTIDE 14 MG IN ACHIEVE-3</p></li></ul><p>Further company coverage: <span>LLY.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Lilly's Orforglipron Outperforms Oral Semaglutide Across Primary & Key Secondary Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Lilly's Orforglipron Outperforms Oral Semaglutide Across Primary & Key Secondary Endpoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-26 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Lilly's Orforglipron Outperforms Oral Semaglutide Across Primary &amp; Key Secondary Endpoints</title></head><body><p><span>Feb 26 (Reuters)</span><span> - </span>Eli Lilly and Co <span>LLY.N</span>:</p><ul><li><p>LILLY'S ORAL GLP-1, ORFORGLIPRON, DELIVERED SUPERIOR BLOOD SUGAR CONTROL &amp; WEIGHT LOSS VERSUS ORAL SEMAGLUTIDE IN TYPE 2 DIABETES TRIAL</p></li><li><p>ELI LILLY: IN ACHIEVE-3, ORFORGLIPRON OUTPERFORMED ORAL SEMAGLUTIDE ACROSS PRIMARY &amp; ALL KEY SECONDARY ENDPOINTS</p></li><li><p>ELI LILLY: TREATMENT DISCONTINUATION RATES DUE TO ADVERSE EVENTS WERE 9.7% (36 MG) FOR ORFORGLIPRON VERSUS. 4.9% (14 MG) FOR ORAL SEMAGLUTIDE</p></li><li><p>ELI LILLY: SUBMITTED ORFORGLIPRON TO REGULATORS IN OVER 40 COUNTRIES, WITH POTENTIAL US ACTION FOR OBESITY IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>ELI LILLY: IN KEY SECONDARY ENDPOINT, PARTICIPANTS ON ORFORGLIPRON 36 MG LOST 19.7 LBS (9.2%) VERSUS 11.0 LBS (5.3%) WITH ORAL SEMAGLUTIDE 14 MG</p></li><li><p>ELI LILLY: ORFORGLIPRON SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE ACROSS KEY CARDIOVASCULAR RISK FACTORS</p></li><li><p>ELI LILLY: FOR PRIMARY ENDPOINT, ORFORGLIPRON 36 MG LOWERED A1C BY 2.2% VERSUS. 1.4% WITH ORAL SEMAGLUTIDE 14 MG IN ACHIEVE-3</p></li></ul><p>Further company coverage: <span>LLY.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2756315664.SGD","symbol_name":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nP8N3RA0FS:1","article_id":"2614416950","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614416950","pubTimestamp":1772105415,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Lilly's Orforglipron Outperforms Oral Semaglutide Across Primary & Key Secondary EndpointsFeb 26  - Eli Lilly and Co LLY.N:LILLY'S ORAL GLP-1, ORFORGLIPRON, DELIVERED SUPERIOR BLOOD SUGAR CONTROL & WEIGHT LOSS VERSUS ORAL SEMAGLUTIDE IN TYPE 2 DIABETES TRIALELI LILLY: IN ACHIEVE-3, ORFORGLIPRON OUTPERFORMED ORAL SEMAGLUTIDE ACROSS PRIMARY & ALL KEY SECONDARY ENDPOINTSELI LILLY: TREATMENT DISCONTINUATION RATES DUE TO ADVERSE EVENTS WERE 9.7%  FOR ORFORGLIPRON VERSUS. 4.9%  FOR ORAL SEMAGLUTIDEELI LILLY: SUBMITTED ORFORGLIPRON TO REGULATORS IN OVER 40 COUNTRIES, WITH POTENTIAL US ACTION FOR OBESITY IN Q2 2026ELI LILLY: IN KEY SECONDARY ENDPOINT, PARTICIPANTS ON ORFORGLIPRON 36 MG LOST 19.7 LBS  VERSUS 11.0 LBS  WITH ORAL SEMAGLUTIDE 14 MGELI LILLY: ORFORGLIPRON SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE ACROSS KEY CARDIOVASCULAR RISK FACTORSELI LILLY: FOR PRIMARY ENDPOINT, ORFORGLIPRON 36 MG LOWERED A1C BY 2.2% VERSUS. 1.4% WITH ORAL SEMAGLUTIDE 14 MG IN ACHIEVE-3Furth","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2168564495.EUR":"AZ ALLOCATION - TREND \"AI\" (EUR) ACC","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","BK4534":"瑞士信贷持仓","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","IE00B4JS1V06.HKD":"JANUS HENDERSON BALANCED \"A2\" (HKD) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4516":"特朗普概念","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU2168564149.EUR":"AZ ALLOCATION - TREND \"BAZ\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LLII":"REX LLY Growth & Income ETF","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LLYX":"2倍做多LLY ETF-Defiance","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4585":"ETF&股票定投概念","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LLYZ":"2倍做空LLY ETF-Defiance","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","SG9999015978.USD":"利安颠覆性创新基金A","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0058720904.USD":"联博国际健康护理基金A","IE00B775H168.HKD":"JANUS HENDERSON BALANCED \"A5M\" (HKD) INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","IE00BN29S564.USD":"JANUS HENDERSON BALANCED \"A3\" (USD) INC","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU2063271972.USD":"富兰克林创新领域基金","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","BK4588":"碎股","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0079474960.USD":"联博美国增长基金A","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0109391861.USD":"富兰克林美国机遇基金A Acc","BK4599":"减肥药","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","IE0001KFT4U8.USD":"FTGF CLEARBRIDGE GLOBAL GROWTH LEADERS \"A\" (USD) INC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LLY":"礼来","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0385154629.USD":"贝莱德营养科学基金A2","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4007":"制药","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU2896262040.SGD":"JPM US GROWTH FUND \"A\" (SGD) ACC","ELIL":"2倍做多LLY ETF-Direxion","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","ELIS":"1倍做空LLY ETF-Direxion","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","BK4581":"高盛持仓","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC"},"translate_title":"简介-礼来公司的Orforglipron在主要和关键次要终点方面优于口服索马鲁肽","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLYX":0.6,"ELIS":0.6,"ELIL":0.6,"LLY":1.98,"LLII":0.6,"LLYZ":0.6},"content_text":"BRIEF-Lilly's Orforglipron Outperforms Oral Semaglutide Across Primary & Key Secondary EndpointsFeb 26 (Reuters) - Eli Lilly and Co LLY.N:LILLY'S ORAL GLP-1, ORFORGLIPRON, DELIVERED SUPERIOR BLOOD SUGAR CONTROL & WEIGHT LOSS VERSUS ORAL SEMAGLUTIDE IN TYPE 2 DIABETES TRIALELI LILLY: IN ACHIEVE-3, ORFORGLIPRON OUTPERFORMED ORAL SEMAGLUTIDE ACROSS PRIMARY & ALL KEY SECONDARY ENDPOINTSELI LILLY: TREATMENT DISCONTINUATION RATES DUE TO ADVERSE EVENTS WERE 9.7% (36 MG) FOR ORFORGLIPRON VERSUS. 4.9% (14 MG) FOR ORAL SEMAGLUTIDEELI LILLY: SUBMITTED ORFORGLIPRON TO REGULATORS IN OVER 40 COUNTRIES, WITH POTENTIAL US ACTION FOR OBESITY IN Q2 2026ELI LILLY: IN KEY SECONDARY ENDPOINT, PARTICIPANTS ON ORFORGLIPRON 36 MG LOST 19.7 LBS (9.2%) VERSUS 11.0 LBS (5.3%) WITH ORAL SEMAGLUTIDE 14 MGELI LILLY: ORFORGLIPRON SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE ACROSS KEY CARDIOVASCULAR RISK FACTORSELI LILLY: FOR PRIMARY ENDPOINT, ORFORGLIPRON 36 MG LOWERED A1C BY 2.2% VERSUS. 1.4% WITH ORAL SEMAGLUTIDE 14 MG IN ACHIEVE-3Further company coverage: LLY.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}